Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase NA 1Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Renal Cell 10Kidney Neoplasms 5Neoplasms 4Gastrointestinal Stromal Tumors 4Breast Neoplasms 2Thyroid Neoplasms 1Somatostatinoma 1Solid Tumors 1Refractory Solid Tumors 1Neoplasm Metastasis 1Glioma 1Gastrointestinal Neoplasms 1Fatigue 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Adenoma, Islet Cell 1

Interventions

Wound Healing 1Sunitinib 1Radiofrequency Ablation 1Plastic Surgery Procedures 1Methods 1Endoscopic Ultrasound-Guided Fine Needle Aspiration 1Doxorubicin 1Cytoreduction Surgical Procedures 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Adenoma, Islet Cell × Sunitinib × Clear all
NCT00428220 2019-06-27

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Pfizer

Phase NA Completed
223 enrolled 8 charts
BreastGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Adenoma, Islet Cell, Somatostatinoma, Thyroid Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡